Versant Venture Capital
Venture capitalSan Francisco
Fund manager profile
Versant Venture Capital is a venture fund manager based in San Francisco. SEC filings show 5 venture funds on record, most recently Versant Venture Capital IX, L.P. ($600.4M offering) filed April 2023.
Source: SEC EDGAR Form D filings. Firm website data not yet available.
What they invest in
from 5 of 5 portfolio companiesBiotech ×5Healthtech ×2Medical Devices ×1
HQs:United States×4
Investments · 5 tracked
founders shown can be your intro pathBy year:2023 · 12020 · 22016 · 12015 · 15 dated
858 Therapeutics is a clinical-stage biotechnology company developing therapies that target tumor dependencies in DNA damage response pathways for patients with advanced solid tumors.
BiotechHealthtechSan Diego, US
James Veal(Executive Officer)Jane Huang(Director)Stafford Jeffrey(Executive Officer, Director)Katherine Bell-McGuinn(Executive Officer)
BoardMonal Mehta(Director)Ali Behbahani(Director)
Board seatBradley J. BolzonClare Ozawa· per SEC Form D · $37.5M raise · filed Mar 2020
Co-investorsNew Enterprise Associates (NEA)Versant Ventures
BiotechBasel
Sven Ante Lundberg(Executive Officer)Thomas Woiwode(Director)Pablo Cagnoni(Director)Bradley Bolzon(Director)N. Anthony Coles(Director)Kala Subramanian(Executive Officer)
Board seatBradley Bolzon· per SEC Form D · $35M raise · filed Nov 2016
Co-investorsAbingworthNew Enterprise Associates (NEA)SR One Capital Management
BiotechSan Diego, US
Petpiboon Prasit(Executive Officer, Director)
BoardClare Ozawa(Executive Officer, Director)
Board seatBradley BolzonJerel DavisThomas Woiwode· per SEC Form D · $19.1M raise · filed Dec 2015
Lycia Therapeutics is a biotechnology company developing LYTAC (Lysosomal Targeting Chimera) therapeutics that bind disease-causing extracellular and cell-surface proteins and route them into the cell's lysosome for degradation.
BiotechHealthtechSouth San Francisco, US
Aetna Wun Trombley(President and CEO)Amy Bachrodt(Chief Financial Officer)Jeremy S. Caldwell(Executive Officer, Director)Chin Lee(Chief Medical Officer)Steve Staben(Chief Scientific Officer)Sofia Touami(Chief Business Officer)
Board seatClare OzawaThomas Woiwode· per SEC Form D · $70.1M raise · filed Sep 2021
Co-investorsREDMILEVersant VenturesBAM ElevateFranklin TempletonHBM Healthcare InvestmentsInvus+4 more
Santa Ana Bio develops engineered antibodies targeting immune system pathways to treat autoimmune and inflammatory diseases.
BiotechMedical DevicesAlameda, US
Peter Emtage(Founder & CEO)inAlexander Rudensky(Scientific Founder)Richard Flavell(Scientific Founder)Graham Lord(Scientific Founder)Ansuman Satpathy(Scientific Founder)
Board seatJerel DavisThomas Woiwode· per SEC Form D · $70.3M raise · filed Feb 2023
Co-investorsAccess BiotechnologyAndreessen HorowitzGV (Google Ventures)Versant Ventures
Rows marked “SEC filing” are inferred from directors named on the company's SEC Form D — public regulatory data, not a portfolio list published by the firm.
Portfolio news
latest coverage across their companies
Lycia Therapeutics · intelligence360.news · Jul 22, 2026
Fund performance · per public LP disclosures
as of Jun 2020| Fund | Vintage | Committed | Net IRR | TVPI | DPI |
|---|---|---|---|---|---|
| Versant Venture Capital I, L.P.LPs: The Regents of the University of California | 1999 | — | 10.2% | 2.02x | 2.02x |
Source: public limited-partner disclosures (CalPERS, CalSTRS). Net IRR / TVPI / DPI as reported by the limited partner; a fund's early-year IRR is an interim estimate (J-curve).
Frequently asked questions
- Where is Versant Venture Capital located?
- Versant Venture Capital is headquartered in San Francisco, US.